HTA bodies

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

Liver Cancer Is Moving Beyond TACE Alone

ctDNA Is Becoming the New Argument Over Chemotherapy

AI can flag hidden cardiac risk. The dangerous part is what health systems do next

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.

Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing

Desmoid Tumours Are Not Benign to the People Living With Them

Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
